USPTO serial 98308022
NOVARTIS
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SONNEBORN, TRICIA L
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with NOVARTIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $449*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software for the facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields; downloadable software in the nature of a mobile application for facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields | ACTIVE | — |
| 010 | Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for the diagnosis, prevention and treatment of haematology diseases and disorders; medical apparatus and instruments for use in tissue and organ transplantation surgery; medical apparatus and instruments for the diagnosis, prevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosis, prevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of immune system related diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of kidney diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention and treatment of hypertension; medical apparatus and instruments for the diagnosis, prevention and treatment of skin disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of urinary diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of ophthalmological diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of respiratory diseases and asthma; radiological apparatus and instruments for medical use; genetic testing apparatus and instruments for medical use; electromagnetic drug delivery apparatus and instruments for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments for DNA and RNA testing for medical use; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments for introducing pharmaceutical preparations into the human body | ACTIVE | — |
| 041 | Providing on-line journals, namely, blogs in the medical, pharmaceutical and health fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 8, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 7, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 7, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 8, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 6, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 5, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 5, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 1, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 31, 2025 | NOAC | CORRECTED NOA E-MAILED | — |
| Dec 31, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 31, 2025 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Dec 30, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 1, 2025 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jul 1, 2025 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jul 1, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 30, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 7, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 7, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 7, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 9, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 14, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 9, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 9, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 8, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 12, 2024 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 12, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 11, 2023 | NWAP | NEW APPLICATION ENTERED | — |